Abstract
Extensive efforts have been expended in the area of serological detection to tumor diagnosis. Basically this area of study has been evaluated using three distinct immunologic approaches. The first encompasses tests which detect immune responses to tumor “putative” specific antigens; in the case of human cancer little success has been achieved. A closely related endeavor has been made to develop assays which measure impairment of the immune response caused by tumor products, ie, an attempt to serologically measure the delayed hypersensitivity defect. Again, equivalent blood assays to measure this immune parameter have not found general acceptance in the clinical laboratory. Noteworthy success has been achieved by a third approach, the development of assays which detect antigens associated with neoplasms, termed tumor-associated antigens (TAAs). A major shortcoming of these assays is that the TAAs presently identified demonstrate cross reactivity with normal adult tissue counterparts, as well as share inherent properties with embryonic or fetal tissues, thereby negating tumor specificity.
Keywords
- Prostatic Acid Phosphatase
- ADCC Activity
- Cyst Disease Fluid Protein
- Cinoembryonic Antigen
- Delay Type Hypersensitivity Skin
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aisenberg AC, Wilkes BM. 1980. Unusual human lymphoma phenotype defined by monoclonal antibody. J Exp Med 152:1126–1131.
Minowada J, Sagawa K, Trowbridge IS, Kung PC, Goldstein G. 1982. Marker profiles of 55 human leukemia-lymphoma cell lines. In; Malignant Lymphomas: Etiology, Immunology, Pathology and Treatment, Rosenberg SA, Kaplan HS, eds. New York, Academic Press, pp 53–74.
Knowles DM, Halper JP, Azzo W, Wang CY. 1983. Reactivity of monoclonal antibodies Leu 1 and OKT2 with malignant human lymphoid cells. Cancer 52:1369–1377.
Greaves MF. 1982. Phenotypic diversity of T cell leukemias. J Clin Immunol (suppl) 2: 75S–80S.
Janossy G, Ganeshaguru K, Hoffbrand AV. 1982. Leukaemia and lymphoma: recent immunological and biochemical developments. In: Recent Advances In Haematology, Vol 3, Hoffbrand AV, ed. Edinburgh, Churchill Livingston, pp 207–231.
Greaves MF, Delia D, Robinson J, Sutherland R, Newman R. 1981. Exploitation of monoclonal antibodies: a “who’s who” of haemopoietic malignancy. Blood Cells 7:257–280.
Greaves M, Delia D, Sutherland R, Rao J, Verbi W, Kemshead J, Hariri G, Goldstein G, Kung P. 1981. Expression of the OKT monoclonal antibody defined antigenic determinants in malignancy. Int J Immunopharmacol 3:283–299.
Greaves MF, Rao J, Hariri G, Verbi W, Catovsky D, Kung P, Goldstein G. 1981. Phenotypic heterogeneity and cellular origins of T cell malignancies. Leuk Res 5:281–299.
Knowles DM, Tolidjian B, Marboe CC, Mittler RS, Talle MA, Goldstein G. 1984. Distribution of antigens defined by OKB monoclonal antibodies on benign and malignant lymphoid cells and on nonlymphoid tissues. Blood 63:886–896.
Ritz J, Pesando JM, McConarty JN, Lazarus H, Schlossman SF. 1980. A monoclonal antibody to human acute lymphoblastic leukemia antigen. Nature 283:583–585.
Mertelsman R, Mertelsman I, Koziner B, Moore MAS, Clarkson BD. 1978. Improved biochemical assay for terminal deoxynucleotidyl transferase in human blood cells: results in 80 adult patients with lymphoid leukemias and malignant lymphomas in leukemic phase. Leuk Res 2:57–62.
Foon KA, Schroff RW, Gale RP. 1982. Surface markers on leukemia and lymphoma cells: recent advances. Blood 60:1–17.
Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF. 1979. Hybrid myeloma monoclonal antibodies against MHC products. Immunol Rev 47:3–61.
Norgaard-Pedersen B, Axelsen NH, eds. 1978. Carcinoembryonic Proteins: Recent Progress, Vol 8. London, Blackwell Scientific Publications, pp 27–38.
Norgaard-Pedersen B, Axelsen NH, eds. 1978. Carcinoembryonic Proteins: Recent Progress, Vol 8. London, Blackwell Scientific Publications, pp 3–26.
Norgaard-Pedersen B, Axelsen NH, eds. 1978. Carcinoembryonic Proteins: Recent Progress, Vol 8. London, Blackwell Scientific Publications, pp 55–64.
Ablin RJ. 1981. Prostatic acid phosphatase: a look and word of caution. Allergol Immunopathol 9:357–358.
Haagensen DE Jr, Barry WF Jr, McCook CA, et al. 1980. The value of serial plasma levels of carcinoembryonic antigen and gross cyst disease fluid protein in patients with breast carcinoma and osseous metastases. Ann Surg 191:599–603.
Sears H, Herlyn J, DelVillano B, Steplewski Z, Koprowski H. 1982. Monoclonal antibody detection of a circulating tumor-associated antigen: II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol 2:141–149.
Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887.
Goldenberg DM, Pant KD. 1976. Colonic cancer-associated antigens in a heterografted human tumor, GW-39. In: Onco-develop-mental gene expression, Fishman WH, Sell S, eds. New York, Academic Press, pp 617–620.
Hansen HJ, Snyder JJ, Miller E, Vandevoorde JP, Miller ON, Hines LR, Burns JJ. 1974. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 5:139–147.
Chu TM, Holyoke ED, Murphy GP. 1974. Carcinoembryonic antigen. Current clinical status. NY State J Med 74:1388–1398.
Houstek J, Masopust J, Kithier K, Radio J. 1968. Hepatocellular carcinoma in association with a specific fetal alpha-1-globulin fetoprotein. J Pediatr 72:186–193.
Sakuragi N. 1982. Serum SPI and hCG beta-subunit (hCG beta) levels in choriocarcinoma, invasive mole, and hydatiform mole-- clinical significance of SPI/hCG beta ratio. Gynecol Oncol 13:393–398.
Mesa-Tejada R, personal communication.
Herberman RB. 1977. Immunologic tests in diagnosis of cancer. Am J Clin Pathol 68:688–698.
Hellstrom I, Hellstrom KE, Sjogren HO, et al. 1971. Demonstration of cell-mediated immunity to human neoplasia of various histological types. Int J Cancer 7:1–16.
Whittaker MG, Rees K, Clark CG. 1971. Reduced lymphocyte transformation in breast cancer. Lancet 1:892–893.
Miller DG. 1968. The immunologic capability of patients with lymphoma. Cancer Res 28:1441–1448.
Reckel RT, Harris J, Botsko E, Wellerson R, Varga S. 1985 (in press). Detection of circulating immune complexes containing Clq-IgG using a new rapid serum ELISA test system. Diag Immunol.
Dent PB, Louis JA, McCulloch PB, Dunnett CW, Cerottini J-C. 1980. Correlation of elevated Clq binding activity and car-cinoembryonic antigen levels with clinical features and prognosis in bronchogenic carcinoma. Cancer 45:130–136.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Hansen, H. (1985). Serologic Approaches to Tumor Diagnosis. In: Pattengale, P.K., Lukes, R.J., Taylor, C.R. (eds) Lymphoproliferative Diseases: Pathogenesis, Diagnosis, Therapy. Developments in Oncology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-5016-0_9
Download citation
DOI: https://doi.org/10.1007/978-94-009-5016-0_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8721-6
Online ISBN: 978-94-009-5016-0
eBook Packages: Springer Book Archive